Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Storey

Showing results (291-300 of 401) with videos related to

Pageof 41
Sort By:
Circulation. Cardiovascular Interventions|July 11, 2020
Nonculprit Lesion Plaque Morphology in Patients With ST-Segment-Elevation Myocardial Infarction: Results From the COMPLETE Trial Optical Coherence Tomography SubstudysNatalia Pinilla-Echeverri, Shamir R Mehta, Jia Wang, et al.
European Heart Journal|July 13, 2023
Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and HaemostasisBruna Gigante, Jerrold H Levy, Eric van Gorp, et al.
Atherosclerosis|July 5, 2011
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Alberico L Catapano, Zeljko Reiner, et al.
European Heart Journal|June 30, 2011
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Zeljko Reiner, Alberico L Catapano, et al.
Circulation|October 31, 2013
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trialLars Wallentin, Daniel Lindholm, Agneta Siegbahn, et al.
Kardiologia Polska|January 5, 2016
[2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation]Marco Roffi, Carlo Patrono, Jean-Philippe Collet, et al.
Thrombosis and Haemostasis|May 20, 2016
P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC studyJohanne Silvain, Robert F Storey, Guillaume Cayla, et al.
American Heart Journal|June 4, 2018
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysisBenjamin M Scirica, Sameer Bansilal, Farideh Davoudi, et al.
Thrombosis and Haemostasis|June 7, 2018
Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study)Wael Sumaya, William A E Parker, Rebekah Fretwell, et al.
Atherosclerosis|September 2, 2011
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)Alberico L Catapano, Zeljko Reiner, Guy De Backer, et al.
Pageof 41

Showing results (291-300 of 401) with videos related to

Sort By:
Pageof 41
Circulation. Cardiovascular Interventions|July 11, 2020
Nonculprit Lesion Plaque Morphology in Patients With ST-Segment-Elevation Myocardial Infarction: Results From the COMPLETE Trial Optical Coherence Tomography SubstudysNatalia Pinilla-Echeverri, Shamir R Mehta, Jia Wang, et al.
European Heart Journal|July 13, 2023
Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and HaemostasisBruna Gigante, Jerrold H Levy, Eric van Gorp, et al.
Atherosclerosis|July 5, 2011
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Alberico L Catapano, Zeljko Reiner, et al.
European Heart Journal|June 30, 2011
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Zeljko Reiner, Alberico L Catapano, et al.
Circulation|October 31, 2013
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trialLars Wallentin, Daniel Lindholm, Agneta Siegbahn, et al.
Kardiologia Polska|January 5, 2016
[2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation]Marco Roffi, Carlo Patrono, Jean-Philippe Collet, et al.
Thrombosis and Haemostasis|May 20, 2016
P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC studyJohanne Silvain, Robert F Storey, Guillaume Cayla, et al.
American Heart Journal|June 4, 2018
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysisBenjamin M Scirica, Sameer Bansilal, Farideh Davoudi, et al.
Thrombosis and Haemostasis|June 7, 2018
Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study)Wael Sumaya, William A E Parker, Rebekah Fretwell, et al.
Atherosclerosis|September 2, 2011
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)Alberico L Catapano, Zeljko Reiner, Guy De Backer, et al.
Pageof 41